Zorevunersen treatment for children with Dravet syndrome
Official title: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Run by Stoke Therapeutics, Inc · NCT06872125 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This trial will test whether zorevunersen can reduce major motor seizures and improve behavior and quality of life in children aged 2–17 with Dravet syndrome.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 2 Years to 17 Years |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | Stoke Therapeutics, Inc Industry-sponsored |
| Locations | 61 sites (Phoenix, Arizona and 60 other locations) |
| Trial ID | NCT06872125 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 2 to under 18 with a clinical diagnosis of Dravet syndrome, a pathogenic/likely pathogenic SCN1A variant or variant of uncertain significance, and the required baseline count of major motor seizures.
✕Probably not a fit
Patients without an identified SCN1A variant, adults, or those whose seizures are caused by other known etiologies are unlikely to be eligible or to benefit from this targeted ASO approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Zorevunersen is an antisense oligonucleotide designed to increase productive SCN1A mRNA and restore Nav1.1 protein levels from the nonmutant SCN1A gene copy. The Phase 3 trial is randomized, double-blind, sham-controlled and conducted at multiple centers with two treatment periods; primary and secondary endpoints are assessed after each period. The primary outcome is change from baseline in major motor seizure frequency, and secondary outcomes include behavior, cognition, clinical status, and health-related quality of life. The goal is to determine whether RNA modulation by zorevunersen can lead to disease-modifying benefits in pediatric Dravet patients.
Why it matters
Potential benefit: If successful, zorevunersen could meaningfully reduce disabling seizures and improve daily functioning and quality of life for children with Dravet syndrome.
How similar studies have gone: Antisense oligonucleotide approaches for neurological genetic disorders have shown promise in early-phase trials, and earlier-stage data for zorevunersen/STK-001 suggested signals, but definitive phase 3 efficacy has not been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: 1. Patients must be ≥2 and \<18 years of age. 2. Patients must have a clinical diagnosis of DS confirmed by the Epilepsy Study Consortium, Inc. (ESCI) and as defined by: Onset, prior to 12 months (inclusive, \<13 months), of age, of recurrent focal with motor signs, hemiclonic, or generalized tonic-clonic seizures. No other known etiology causing clinical DS manifestations.. 3. Patient must have a documented pathogenic, likely pathogenic variant, or variant of uncertain significance in the sodium voltage-gated channel type 1 alpha subunit (SCN1A) gene. Patients who have SCN1A testing results of Negative (no variants identified) cannot be randomized. 4. Patient must experience the required number of major motor seizures during the 6-week Observation Period. Major motor seizure types included are Seizure types included in counts are Hemiclonic, Focal with Motor Signs, Focal to Bilateral Tonic-Clonic, Generalized Tonic-Clonic, Tonic, Tonic/Atonic (Drop Attacks with fall or risk of fall), and Bilateral Clonic. 5. Patient must have used at least 2 prior interventions for seizures. These can include anti-seizure medications (ASMs), ketogenic diet and/or vagus nerve stimulation (VNS) with either lack of adequate seizure control or discontinued due to an AE(s). These interventions can be ongoing therapies. 6. Patient must be taking at least one ASM. Benzodiazepines or ASMs used on a standing basis (i.e., not as needed \[PRN\]) for any indication will be considered an ASM. 7. Patients' maintenance ASMs and interventions for seizures (i.e., ketogenic diet or VNS), as well as any marijuana- or cannabinoid-based products, must have been stable (unless adjusted for weight) during the Baseline Period. Key Exclusion Criteria: 1. Patient has documented variant in the SCN1A gene associated with gain-of-function 2. Patient is currently treated with a maintenance ASM acting primarily as a sodium channel blocker, including but not limited to phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, rufinamide, or cenobamate, given the mechanism of action of zorevunersen. 3. Patient is currently treated with neuromodulation techniques (e.g., responsive neurostimulation, deep brain stimulation, or transcranial magnetic stimulation), with the exception of VNS. 4. Patient has emergence of a new seizure type or reemergence of a past seizure type (seizure types that last occurred more than 12 months before Screening Visit A) during the Baseline Period, or has more than 1 hospitalization for seizures during the Baseline Period.
Where it's running
-
Phoenix Children's Hospital
Phoenix, Arizona, United States Recruiting -
Arkansas Children's Hospital
Little Rock, Arkansas, United States Recruiting -
Cedars Sinai Medical Center
Los Angeles, California, United States Recruiting -
Children's Hospital of Orange County
Orange, California, United States Recruiting -
USCF Medical Center
San Francisco, California, United States Recruiting -
Children's Hospital Colorado
Aurora, Colorado, United States Recruiting
Show 44 more locations
-
Children's National Medical Center
Washington D.C., District of Columbia, United States Recruiting -
Nemours Children's Health
Jacksonville, Florida, United States Recruiting -
Nicklaus Children's Hospital
Miami, Florida, United States Recruiting -
Advent Health Neuroscience Research Institute
Orlando, Florida, United States Recruiting -
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Boston Children's Hospital
Boston, Massachusetts, United States Recruiting -
CS Mott Children's Hospital
Ann Arbor, Michigan, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Recruiting -
NYU Langone Health
New York, New York, United States Recruiting -
Weill Cornell Medicine
New York, New York, United States Recruiting -
University of Rochester Medical Center
Rochester, New York, United States Recruiting -
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States Recruiting -
Duke University Health System
Durham, North Carolina, United States Recruiting -
Cleveland Clinic
Cleveland, Ohio, United States Recruiting -
Nationwide Children's Hospital
Columbus, Ohio, United States Recruiting -
Oregon Health & Science University (OHSU)
Portland, Oregon, United States Recruiting -
LeBonheur Children's Hospital
Memphis, Tennessee, United States Recruiting -
Cook Children's Medical Center
Fort Worth, Texas, United States Recruiting -
Texas Children's Hospital
Houston, Texas, United States Recruiting -
University of Utah Primary Children's Hospital
Salt Lake City, Utah, United States Recruiting -
UVA Health
Charlottesville, Virginia, United States Recruiting -
Hôpital de la Timone
Marseille, France Recruiting -
Hôpital Necker - Enfants Malades
Paris, France Recruiting -
Hôpital Robert Debré - Paris
Paris, France Recruiting -
Charité - Campus Virchow-Klinikum
Berlin, Germany Recruiting -
Universitaetsklinikum Bonn AoeR
Bonn, Germany Recruiting -
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt, Germany Recruiting -
Universitaetsklinikum Freiburg
Friedberg, Germany Recruiting -
Universitaetsklinikum Heidelberg
Heidelberg, Germany Recruiting -
Integriertes Sozialpaediatrisches Zentrum
München, Germany Recruiting -
Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
Florence, Italy Recruiting -
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
Genova, Italy Recruiting -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy Recruiting -
Ospedale Pediatrico Bambino Gesù
Roma, Italy Recruiting -
Fukuoka Children's Hospital
Fukuoka, Japan Recruiting -
Hokkaido University Hospital
Hokkaido, Japan Recruiting -
Kyoto University Hospital
Kyoto, Japan Recruiting -
Nagoya University Hospital
Nagoya, Japan Recruiting -
National Hospital Organization Nishi Niigata Central Hospital
Niigata, Japan Recruiting -
Okayama University Hospital
Okayama, Japan Recruiting -
Osaka City General Hospital
Osaka, Japan Recruiting -
Jichi Medical University Hospital
Shimotsuke, Japan Recruiting -
NHO Shizuoka
Shizuoka, Japan Recruiting
+11 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Emperor Information Center
- Email: info@emperorstudy.com
- Phone: 1-781-430-8200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ION337 safety and tolerability in children with Dravet syndrome
This will test whether ION337 is safe and well tolerated in children ages 2 to 12 with Dravet syndrome.
-
Tracking development, seizures, and biomarkers over four years in children and young adults with SCN1A-related Dravet syndrome
This project will follow children and young people with SCN1A-related Dravet syndrome for four years to see how their development, seizure patterns, and blood metabolite markers change over time.
-
Fintepla for Dravet Syndrome: testing brain blood flow and connections
This study tests how Fintepla affects brain blood flow and network connections in Dravet syndrome patients who have convulsive seizures.
-
PET‑MRI mapping of brainstem serotonin pathways in adults with Dravet syndrome
This uses a PET‑MRI scan with the tracer [18F]MPPF to see if serotonin pathways in the brainstem differ in adults with Dravet syndrome compared with healthy controls.
-
Testing BMB-101 for Absence Epilepsy and Related Conditions
This study is testing a new treatment called BMB-101 to see if it can help reduce seizures in people with Absence Epilepsy and related conditions.
-
Measuring GABA Levels in Children with Dravet Syndrome
This study is trying to measure GABA levels in the brains of children with Dravet Syndrome to see how they compare to kids without the condition, hoping to find new ways to understand and treat the syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.